Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RV3-BB Dose-Ranging in Neonates and Infants
NCT03483116Phase 2Completed
- Sponsor
- Murdoch Children's Research Institute
- Start
- Jun 2018
- Primary completion
- Jan 2020
- Modality
- Live Attenuated Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of RV3-BB in rotavirus infection, sponsored by Murdoch Children's Research Institute. Started Jun 2018; status: completed.
02
Drugs
RV3-BB
03
Conditions
rotavirus infection
Beyond the preview
Go deeper on NCT03483116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03483116.